GGrantIndex
← Leaderboards

Jack R Cornelius

University Of Pittsburgh At Pittsburgh

Google Scholar ↗PubMed ↗ORCID ↗
$10,996,261
Attributed
$10,996,261
Total exposure
8
Grants
7
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $1.5M · FY2005–16
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16

Funding mix

By agency

NIH$10,996,261 · 8

By mechanism

R01$6,170,386 · 3
P50$3,450,387 · 2
R21$800,374 · 2
K24$575,114 · 1

Top collaborators

No co-investigators on record.

Most similar at University Of Pittsburgh At Pittsburgh

Same institution · by research overlap

Others in their field

Top investigators on “Placebos”

Research focus

PlacebosComorbidityChildAdultSamplingFluoxetineAlcohol ConsumptionAcuteDepressive SymptomsAlcohol Use DisorderPilot ProjectsDrinkingAntidepressive AgentsSelective Serotonin Reuptake InhibitorMajor Depressive DisorderPlacebo Controlled StudyDouble-Blind MethodPharmaceutical PreparationsEvaluationFollow-UpBaseAlcohol DependenceAlcohol Abuse TherapyPlacebo Control

Grant awards (35)

Treatment of Young Adults with Comorbid AUD/MDD: A Pilot Medication Trial$182,875
R21 · FY2016 · AA · contact PI
Treatment of Young Adults with Comorbid AUD/MDD: A Pilot Medication Trial$221,375
R21 · FY2015 · AA · contact PI
Clinical Core$476,953
P50 · FY2014 · DA · contact PI
Double-blind pilot trial of mirtazapine for the treatment of co-occurring AD/MDD$214,733
R21 · FY2014 · AA · contact PI
Clinical Core$428,887
P50 · FY2013 · DA · contact PI
Double-blind pilot trial of mirtazapine for the treatment of co-occurring AD/MDD$181,391
R21 · FY2013 · AA · contact PI
Clinical Core$447,541
P50 · FY2012 · DA · contact PI
Clinical Core$451,166
P50 · FY2011 · DA · contact PI
Clinical Core$543,626
P50 · FY2010 · DA · contact PI
Fluoxetine for MDD/Cannabis Disorder in Young People$424,905
R01 · FY2009 · DA · contact PI
FLUOXETINE-TREATED AUD-MDD TEENS: LONG TERM OUTCOMES$316,810
R01 · FY2009 · AA · contact PI
Fluoxetine for MDD/Cannabis Disorder in Young People$124,230
R01 · FY2009 · DA · contact PI
Psychopathology in Pharmacotherapy of AUD/MDD Teens$120,412
K24 · FY2009 · AA · contact PI
FLUOXETINE-TREATED AUD-MDD TEENS: LONG TERM OUTCOMES$316,810
R01 · FY2008 · AA · contact PI
CLINICAL CORE$230,014
P50 · FY2008 · DA · contact PI
Psychopathology in Pharmacotherapy of AUD/MDD Teens$117,678
K24 · FY2008 · AA · contact PI
Fluoxetine for MDD/Cannabis Disorder in Young People$508,801
R01 · FY2007 · DA · contact PI
FLUOXETINE-TREATED AUD-MDD TEENS: LONG TERM OUTCOMES$316,810
R01 · FY2007 · AA · contact PI
CLINICAL CORE$267,307
P50 · FY2007 · DA · contact PI
Psychopathology in Pharmacotherapy of AUD/MDD Teens$115,010
K24 · FY2007 · AA · contact PI
Fluoxetine for MDD/Cannabis Disorder in Young People$509,175
R01 · FY2006 · DA · contact PI
FLUOXETINE-TREATED AUD-MDD TEENS: LONG TERM OUTCOMES$326,272
R01 · FY2006 · AA · contact PI
CLINICAL CORE$204,748
P50 · FY2006 · DA · contact PI
Psychopathology in Pharmacotherapy of AUD/MDD Teens$112,328
K24 · FY2006 · AA · contact PI
Fluoxetine for MDD/Cannabis Disorder in Young People$507,365
R01 · FY2005 · DA
Pharmacological Intervention Project$380,123
R01 · FY2005 · AA
FLUOXETINE-TREATED AUD-MDD TEENS: LONG TERM OUTCOMES$334,125
R01 · FY2005 · AA
CLINICAL CORE$201,088
P50 · FY2005 · DA
Psychopathology in Pharmacotherapy of AUD/MDD Teens$109,686
K24 · FY2005 · AA
Fluoxetine for MDD/Cannabis Disorder in Young People$506,176
R01 · FY2004 · DA
Pharmacological Intervention Project$409,003
R01 · FY2004 · AA
CLINICAL CORE$199,057
P50 · FY2004 · DA
Pharmacological Intervention Project$398,967
R01 · FY2003 · AA
Pharmacological Intervention Project$389,817
R01 · FY2002 · AA
Pharmacological Intervention Project$400,997
R01 · FY2001 · AA